BackgroundDeep stromal invasion (DSI) is one of the predominant risk factors that determined the types of radical hysterectomy (RH). Thus, the accurate assessment of DSI in cervical adenocarcinoma (AC)/adenosquamous carcinoma (ASC) can facilitate optimal therapy decision.PurposeTo develop a nomogram to identify DSI in cervical AC/ASC.Study TypeRetrospective.PopulationSix hundred and fifty patients (mean age of 48.2 years) were collected from center 1 (primary cohort, 536), centers 2 and 3 (external validation cohorts 1 and 2, 62 and 52).Field Strength/Sequence5‐T, T2‐weighted imaging (T2WI, SE/FSE), diffusion‐weighted imaging (DWI, EPI), and contrast‐enhanced T1‐weighted imaging (CE‐T1WI, VIBE/LAVA).AssessmentThe DSI was defined as the outer 1/3 stromal invasion on pathology. The region of interest (ROI) contained the tumor and 3 mm peritumoral area. The ROIs of T2WI, DWI, and CE‐T1WI were separately imported into Resnet18 to calculate the DL scores (TDS, DDS, and CDS). The clinical characteristics were retrieved from medical records or MRI data assessment. The clinical model and nomogram were constructed by integrating clinical independent risk factors only and further combining DL scores based on primary cohort and were validated in two external validation cohorts.Statistical TestsStudent's t‐test, Mann–Whitney U test, or Chi‐squared test were used to compare differences in continuous or categorical variables between DSI‐positive and DSI‐negative groups. DeLong test was used to compare AU‐ROC values of DL scores, clinical model, and nomogram.ResultsThe nomogram integrating menopause, disruption of cervical stromal ring (DCSRMR), DDS, and TDS achieved AU‐ROCs of 0.933, 0.807, and 0.817 in evaluating DSI in primary and external validation cohorts. The nomogram had superior diagnostic ability to clinical model and DL scores in primary cohort (all P < 0.0125 [0.05/4]) and CDS (P = 0.009) in external validation cohort 2.Data ConclusionThe nomogram achieved good performance for evaluating DSI in cervical AC/ASC.Level of Evidence3Technical EfficacyStage 2